CMAB

The term "CMAB" primarily refers to a prefix used by Mabpharm Limited (also known as CMAB Biopharma), a biopharmaceutical company specializing in the research, development, and production of novel drugs and biosimilars, mainly monoclonal antibodies, for the treatment of cancer and autoimmune diseases. Mabpharm Limited utilizes "CMAB" as part of the code names for its pipeline products, such as CMAB007 (Omalizumab α), CMAB008 (Infliximab for Injection), CMAB009 (Cetuximab β Injection), CMAB015 (a Secukinumab biosimilar), CMAB807/CMAB807X (a Denosumab biosimilar), CMAB017 (a probody drug), and CMAB819 (a biosimilar drug candidate). CMAB Biopharma also functions as a Contract Development and Manufacturing Organization (CDMO), providing development and manufacturing services for antibodies and biologics to other clients. It is important to note that "CMAB" is not a specific drug itself, but rather an identifier for a company's product line and services. Unrelated to Mabpharm, "CM-101" is a monoclonal antibody developed by Chemomab Therapeutics targeting CCL24 for fibrotic and inflammatory diseases, and "CmaB" has also been identified as an enzyme involved in coronamic acid biosynthesis.